Sahin, Ilyas <br/><br/>
Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.  [electronic resource] 

 -  American journal of hematology  Nov 2014 
 - 1030-6 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1096-8652 
<br/><br/><label>Standard No.: </label>10.1002/ajh.23814  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aminopyridines--pharmacology<br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Cell Adhesion--drug effects<br/>Cell Cycle--drug effects<br/>Cell Line<br/>Cell Line, Tumor<br/>Chemotaxis--drug effects<br/>Coculture Techniques<br/>Drug Screening Assays, Antitumor<br/>Female<br/>Fibronectins<br/>Humans<br/>Mesenchymal Stem Cells--cytology<br/>Mice<br/>Mice, SCID<br/>Morpholines--pharmacology<br/>Multiple Myeloma--enzymology<br/>Neoplasm Invasiveness<br/>Neoplasm Proteins--antagonists & inhibitors<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Protein Kinase Inhibitors--pharmacology<br/>RNA Interference<br/>RNA, Small Interfering--pharmacology<br/>Receptors, CXCR4--biosynthesis<br/>Waldenstrom Macroglobulinemia--enzymology<br/>Xenograft Model Antitumor Assays